Details of the Drug Combinations

General Information of This Drug (ID: DM15F0X)

Drug Name
Gefitinib   DM15F0X
Synonyms
Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
Indication
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [1]
Glioblastoma 2A00 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Rectal adenocarcinoma 2B92 Approved [1]
Rectum mucinous adenocarcinoma N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Head and neck cancer 2D42 Phase 3 [2]
Urethral cancer 2C93 Phase 2 [2]
Colon cancer 2B90.Z Investigative [1]
Colon mucinous adenocarcinoma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1263 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole + Gefitinib DC9MYUD 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Abacavir + Gefitinib DCX75IS Abacavir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
ABIRATERONE + Gefitinib DCEJMZ9 ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
ABIRATERONE + Gefitinib DCGQ7V4 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [3]
ABIRATERONE + Gefitinib DCVQ7MU ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
ABIRATERONE + Gefitinib DCKKGN5 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [3]
ABIRATERONE + Gefitinib DCJ0MWD ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
ABIRATERONE + Gefitinib DCTX408 ABIRATERONE Glioma (Cell Line: SF-539) [3]
ABIRATERONE + Gefitinib DC8TICB ABIRATERONE Glioma (Cell Line: SF-295) [3]
ABIRATERONE + Gefitinib DCUTS6D ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [3]
ABIRATERONE + Gefitinib DCOS80J ABIRATERONE Carcinoma (Cell Line: MCF7) [4]
ABIRATERONE + Gefitinib DCEVHT9 ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [4]
ABIRATERONE + Gefitinib DCOJGIK ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [4]
ABIRATERONE + Gefitinib DCJEVY6 ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [5]
ABIRATERONE + Gefitinib DCIQHVB ABIRATERONE Adenocarcinoma (Cell Line: A549) [5]
ABIRATERONE + Gefitinib DCGZP1S ABIRATERONE Amelanotic melanoma (Cell Line: M14) [5]
ABIRATERONE + Gefitinib DC1SK0I ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
ABIRATERONE + Gefitinib DCLGJXX ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
ABIRATERONE + Gefitinib DCFN0UD ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [5]
ABIRATERONE + Gefitinib DC6R5F8 ABIRATERONE Lung adenocarcinoma (Cell Line: NCI-H522) [5]
ABIRATERONE + Gefitinib DC8U9XG ABIRATERONE Malignant melanoma (Cell Line: UACC62) [5]
ABIRATERONE + Gefitinib DCHX3QO ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [5]
ABIRATERONE + Gefitinib DCV6PPN ABIRATERONE Melanoma (Cell Line: UACC-257) [5]
ABIRATERONE + Gefitinib DCIM11F ABIRATERONE Melanoma (Cell Line: MALME-3M) [5]
ABIRATERONE + Gefitinib DC98OUG ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
ABIRATERONE + Gefitinib DCOAP76 ABIRATERONE Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
ABIRATERONE + Gefitinib DCJM37R ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
ABIRATERONE + Gefitinib DCKUPQO ABIRATERONE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
ABT-263 + Gefitinib DC5MWB3 ABT-263 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [5]
Acarbose + Gefitinib DC3EIBH Acarbose Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Acetazolamide + Gefitinib DCLTPAM Acetazolamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Aliskiren + Gefitinib DCN37U6 Aliskiren Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Amantadine + Gefitinib DCGI57M Amantadine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Armodafinil + Gefitinib DC8RSXN Armodafinil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Artemisinin + Gefitinib DCKGDCS Artemisinin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
AS-1949490 + Gefitinib DCR4582 AS-1949490 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Asenapine + Gefitinib DCQAWBS Asenapine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Auranofin + Gefitinib DCCTIUR Auranofin Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Auranofin + Gefitinib DCFOYLP Auranofin Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Baclofen + Gefitinib DCBUQ59 Baclofen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Benserazide + Gefitinib DCX9Q9N Benserazide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
BHV-0223 + Gefitinib DCRWL9K BHV-0223 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
BIIB-021 + Gefitinib DCUOZJ7 BIIB-021 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
BMS-754807 + Gefitinib DCS4180 BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
BMS-754807 + Gefitinib DCBXGK2 BMS-754807 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Bortezomib + Gefitinib DCIM3TH Bortezomib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Brincidofovir + Gefitinib DCLTES1 Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
BRL-15572 + Gefitinib DCJDC41 BRL-15572 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
CA4P + Gefitinib DCGV69I CA4P Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Cabazitaxel + Gefitinib DCKHZGJ Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [3]
Cabazitaxel + Gefitinib DC30V72 Cabazitaxel Adenocarcinoma (Cell Line: A549) [3]
Cabazitaxel + Gefitinib DC86YJI Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Cabazitaxel + Gefitinib DCFVIAF Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [3]
Cabazitaxel + Gefitinib DCOK524 Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [3]
Cabazitaxel + Gefitinib DC0YRQU Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [3]
Cabazitaxel + Gefitinib DCB92KF Cabazitaxel Adenocarcinoma (Cell Line: HT29) [3]
Cabazitaxel + Gefitinib DCTGL4Q Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cabazitaxel + Gefitinib DCROFEW Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Cabazitaxel + Gefitinib DCN6MEI Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Cabazitaxel + Gefitinib DCTDBH9 Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cabazitaxel + Gefitinib DCJMZUT Cabazitaxel Astrocytoma (Cell Line: SNB-19) [3]
Cabazitaxel + Gefitinib DC327BD Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cabazitaxel + Gefitinib DCPN0LU Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Cabazitaxel + Gefitinib DCO6BWJ Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Cabazitaxel + Gefitinib DCU2FIQ Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Cabazitaxel + Gefitinib DCXM38D Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Cabazitaxel + Gefitinib DC3HVH3 Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Cabazitaxel + Gefitinib DC7S5DW Cabazitaxel Glioblastoma (Cell Line: SNB-75) [3]
Cabazitaxel + Gefitinib DC4E4H2 Cabazitaxel Glioma (Cell Line: SF-268) [3]
Cabazitaxel + Gefitinib DCJDR8G Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Cabazitaxel + Gefitinib DC4MND6 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Cabazitaxel + Gefitinib DCWYNPL Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Cabazitaxel + Gefitinib DCHEX9B Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cabazitaxel + Gefitinib DCE6M9D Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Cabazitaxel + Gefitinib DCQ3OAC Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cabazitaxel + Gefitinib DCLS0QG Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Cabazitaxel + Gefitinib DCCD0AB Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Cabazitaxel + Gefitinib DCF8UHR Cabazitaxel Melanoma (Cell Line: MALME-3M) [3]
Cabazitaxel + Gefitinib DCKJBGE Cabazitaxel Melanoma (Cell Line: UACC-257) [3]
Cabazitaxel + Gefitinib DCOX7XU Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Cabazitaxel + Gefitinib DCPT5IJ Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Cabazitaxel + Gefitinib DCD033Y Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Cabazitaxel + Gefitinib DCZXY97 Cabazitaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cabazitaxel + Gefitinib DCSZTUH Cabazitaxel Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Cabazitaxel + Gefitinib DCUY2SR Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Cabazitaxel + Gefitinib DCO46O5 Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [3]
Cabazitaxel + Gefitinib DCWROO8 Cabazitaxel Renal cell carcinoma (Cell Line: UO-31) [3]
Cabazitaxel + Gefitinib DC5X2R8 Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Cabazitaxel + Gefitinib DCCKGYI Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Cabazitaxel + Gefitinib DCM5AKC Cabazitaxel Carcinoma (Cell Line: RXF 393) [4]
Cabazitaxel + Gefitinib DC1VYTV Cabazitaxel Carcinoma (Cell Line: MCF7) [4]
Cabazitaxel + Gefitinib DCI9ZMO Cabazitaxel Colon carcinoma (Cell Line: KM12) [4]
Cabazitaxel + Gefitinib DC13P7Y Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [4]
Cabazitaxel + Gefitinib DC8MW52 Cabazitaxel Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Cefmenoxime + Gefitinib DC015H2 Cefmenoxime Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cevimeline + Gefitinib DCXG99I Cevimeline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Chlormezanone + Gefitinib DCKG3DM Chlormezanone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Chlorzoxazone + Gefitinib DCHAW1T Chlorzoxazone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cinacalcet + Gefitinib DC648G4 Cinacalcet Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Citalopram + Gefitinib DCO7VGO Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Clindamycin + Gefitinib DC308A4 Clindamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Clopidogrel + Gefitinib DCHXIAX Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
CPG 52364 + Gefitinib DC6A7MN CPG 52364 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Crizotinib + Gefitinib DC1TVHU Crizotinib Adenocarcinoma (Cell Line: DU-145) [3]
Crizotinib + Gefitinib DC1KF63 Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Crizotinib + Gefitinib DC4JRWH Crizotinib Adenocarcinoma (Cell Line: A549) [3]
Crizotinib + Gefitinib DCZJIFR Crizotinib Adenocarcinoma (Cell Line: NCIH23) [3]
Crizotinib + Gefitinib DC6CMQS Crizotinib Adenocarcinoma (Cell Line: HCT-15) [3]
Crizotinib + Gefitinib DCU6OUW Crizotinib Amelanotic melanoma (Cell Line: M14) [3]
Crizotinib + Gefitinib DCX2I7D Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Crizotinib + Gefitinib DCARD1Y Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Crizotinib + Gefitinib DC7304N Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Crizotinib + Gefitinib DCKNBPZ Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Crizotinib + Gefitinib DC46KHN Crizotinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Crizotinib + Gefitinib DCT1S18 Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Crizotinib + Gefitinib DCINCQQ Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Crizotinib + Gefitinib DCDFGF4 Crizotinib Glioblastoma (Cell Line: SNB-75) [3]
Crizotinib + Gefitinib DCARPXT Crizotinib Glioma (Cell Line: SF-539) [3]
Crizotinib + Gefitinib DCG6SKE Crizotinib Glioma (Cell Line: SF-268) [3]
Crizotinib + Gefitinib DC8M5Y4 Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Crizotinib + Gefitinib DCMD9FS Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Crizotinib + Gefitinib DC6HL3C Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Crizotinib + Gefitinib DC3Y7CT Crizotinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Crizotinib + Gefitinib DCVCIPQ Crizotinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Crizotinib + Gefitinib DCFU1L5 Crizotinib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Crizotinib + Gefitinib DCAMODK Crizotinib Melanoma (Cell Line: UACC-257) [3]
Crizotinib + Gefitinib DC3SS31 Crizotinib Melanoma (Cell Line: SK-MEL-2) [3]
Crizotinib + Gefitinib DCK0PU7 Crizotinib Melanoma (Cell Line: MALME-3M) [3]
Crizotinib + Gefitinib DCEZJP5 Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Crizotinib + Gefitinib DCQHOYY Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Crizotinib + Gefitinib DCK4SM1 Crizotinib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Crizotinib + Gefitinib DC00W1P Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Crizotinib + Gefitinib DCWF6S7 Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Crizotinib + Gefitinib DCO19VA Crizotinib Prostate carcinoma (Cell Line: PC-3) [3]
Crizotinib + Gefitinib DCHMTX0 Crizotinib Renal cell carcinoma (Cell Line: SN12C) [3]
Crizotinib + Gefitinib DCVJKJH Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Crizotinib + Gefitinib DCJ38L2 Crizotinib Colon carcinoma (Cell Line: KM12) [4]
Crizotinib + Gefitinib DCI2CTG Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Crizotinib + Gefitinib DCIAGZG Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Dactinomycin + Gefitinib DCJHP9P Dactinomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Darunavir + Gefitinib DCVKPVE Darunavir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Diazoxide + Gefitinib DC8VVAX Diazoxide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Diphenidol + Gefitinib DCUARDO Diphenidol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Dopamine + Gefitinib DCCDRIQ Dopamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Doxapram + Gefitinib DCR2XBJ Doxapram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Doxorubicin + Gefitinib DCTXMS2 Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Dronedarone + Gefitinib DCQ54DJ Dronedarone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Endoxifen + Gefitinib DCTVZ1E Endoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Enoxacin + Gefitinib DC9WGHJ Enoxacin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Entacapone + Gefitinib DCEUN8R Entacapone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Epirubicin + Gefitinib DCQEO3O Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Gefitinib DCH6SXM Epirubicin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Epirubicin + Gefitinib DCL30CY Epirubicin Astrocytoma (Cell Line: U251) [3]
Epirubicin + Gefitinib DCH4EDP Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Epirubicin + Gefitinib DCY6J8K Epirubicin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Epirubicin + Gefitinib DCBA2L2 Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Epirubicin + Gefitinib DCHDQX3 Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Epirubicin + Gefitinib DCGOPVG Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Epirubicin + Gefitinib DC6Y91Y Epirubicin Glioblastoma (Cell Line: SNB-75) [3]
Epirubicin + Gefitinib DCGLSN4 Epirubicin Glioma (Cell Line: SF-295) [3]
Epirubicin + Gefitinib DCSE9H5 Epirubicin Glioma (Cell Line: SF-539) [3]
Epirubicin + Gefitinib DCOLS8Y Epirubicin Renal cell carcinoma (Cell Line: SN12C) [3]
Epirubicin + Gefitinib DCQRV6O Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Epirubicin + Gefitinib DCP3ZUK Epirubicin Carcinoma (Cell Line: RXF 393) [4]
Epirubicin + Gefitinib DC3SX6G Epirubicin Carcinoma (Cell Line: MCF7) [4]
Epirubicin + Gefitinib DC0STK3 Epirubicin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Epirubicin + Gefitinib DCW54JG Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Epirubicin + Gefitinib DC8O5KI Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Epirubicin + Gefitinib DCA93RG Epirubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Epirubicin + Gefitinib DCEAFVV Epirubicin Adenocarcinoma (Cell Line: A549) [5]
Epirubicin + Gefitinib DC4AAYP Epirubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Epirubicin + Gefitinib DCSNWQ2 Epirubicin Adenocarcinoma (Cell Line: HCT116) [5]
Epirubicin + Gefitinib DCV0B5O Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Epirubicin + Gefitinib DC4YVAG Epirubicin Amelanotic melanoma (Cell Line: M14) [5]
Epirubicin + Gefitinib DC9UFD0 Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Epirubicin + Gefitinib DCJXG4I Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Epirubicin + Gefitinib DCBDT3T Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Epirubicin + Gefitinib DC76Y0N Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Epirubicin + Gefitinib DCCEQMI Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [5]
Epirubicin + Gefitinib DCBTSLH Epirubicin Malignant melanoma (Cell Line: UACC62) [5]
Epirubicin + Gefitinib DCDBPLA Epirubicin Melanoma (Cell Line: UACC-257) [5]
Epirubicin + Gefitinib DCZVB4U Epirubicin Melanoma (Cell Line: SK-MEL-2) [5]
Epirubicin + Gefitinib DC4FQG9 Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Epirubicin + Gefitinib DCTLOEV Epirubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Epirubicin + Gefitinib DCYBXDG Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Epirubicin + Gefitinib DCBUDQ1 Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Ethambutol + Gefitinib DCSBRCI Ethambutol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ethinyl estradiol + Gefitinib DCLEIB1 Ethinyl estradiol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
ETHISTERONE + Gefitinib DC5MIEK ETHISTERONE Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Etonogestrel + Gefitinib DC5966U Etonogestrel Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Everolimus + Gefitinib DC3X54T Everolimus Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Flavonoid derivative 1 + Gefitinib DCGQEHV Flavonoid derivative 1 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fomepizole + Gefitinib DCJRHSV Fomepizole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
FORMESTANE + Gefitinib DC1AGWZ FORMESTANE Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fosfomycin + Gefitinib DCB6IFU Fosfomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Aprepitant DCJMO95 Aprepitant Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Meclofenamic acid DCFJEZP Meclofenamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Ribavirin-TP DCOQQQG Ribavirin-TP Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Mechlorethamine DCLY3VE Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Mechlorethamine DCON7X0 Mechlorethamine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Mechlorethamine DCZR3YA Mechlorethamine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Mechlorethamine DCXKX59 Mechlorethamine Glioma (Cell Line: SF-539) [3]
Gefitinib + Mechlorethamine DCZ09GC Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Mechlorethamine DCIT7PM Mechlorethamine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Sertraline DCI0CPI Sertraline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Pentostatin DCX29Y1 Pentostatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Pentostatin DCBTI86 Pentostatin Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Mebutamate DCMK15N Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Picoplatin DCG96WT Picoplatin Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Picoplatin DCGJKOD Picoplatin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Picoplatin DCAU74Z Picoplatin Glioma (Cell Line: SF-539) [3]
Gefitinib + Picoplatin DC5JMRI Picoplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Fulvestrant DCYN0TA Fulvestrant Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Fulvestrant DCWP914 Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Fulvestrant DCDWRYK Fulvestrant Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Fulvestrant DCB7IGH Fulvestrant Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Fulvestrant DCX0AGX Fulvestrant Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Diethylcarbamazine DCVRUQ6 Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Hepzato DC3W302 Hepzato Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Hepzato DCZDGYE Hepzato Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Hepzato DCUMS1E Hepzato Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Triamterene DCOSAYX Triamterene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Ixabepilone DCHQ3UZ Ixabepilone Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Ixabepilone DCKYLTZ Ixabepilone Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Ixabepilone DCNLLI2 Ixabepilone Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Ixabepilone DCVZ4AG Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Ixabepilone DCAUBNV Ixabepilone Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Ixabepilone DC60EXW Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Ixabepilone DC4BGZX Ixabepilone Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Ixabepilone DC242M6 Ixabepilone Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Crotamiton DC7N639 Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Dactinomycin DCZJYWW Dactinomycin Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Dactinomycin DCDTVQD Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Dactinomycin DCD6SV0 Dactinomycin Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Dactinomycin DC1AVS1 Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Dactinomycin DCSPJG1 Dactinomycin Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Dactinomycin DCHSZQ1 Dactinomycin Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Dactinomycin DCIH5KN Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Dactinomycin DCOBCXC Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + Dactinomycin DC23JHU Dactinomycin Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Dactinomycin DCNFDGX Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Dactinomycin DCNPB7T Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Dactinomycin DCPQA58 Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Gefitinib + Dactinomycin DCD04G4 Dactinomycin Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Dactinomycin DCNNHH3 Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Dactinomycin DCXCTN6 Dactinomycin Astrocytoma (Cell Line: U251) [3]
Gefitinib + Dactinomycin DCMP4I7 Dactinomycin Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Dactinomycin DCXUN37 Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Dactinomycin DC6JKOJ Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Dactinomycin DCCA14W Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Dactinomycin DCHIEML Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Dactinomycin DCX0IJY Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Dactinomycin DCHEKA6 Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Dactinomycin DCWH58V Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Dactinomycin DCV43UF Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Dactinomycin DCEVRV0 Dactinomycin Glioma (Cell Line: SF-295) [3]
Gefitinib + Dactinomycin DCE293G Dactinomycin Glioma (Cell Line: SF-268) [3]
Gefitinib + Dactinomycin DCLL7CU Dactinomycin Glioma (Cell Line: SF-539) [3]
Gefitinib + Dactinomycin DCNN452 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Dactinomycin DCVL31D Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Dactinomycin DCESN2X Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Dactinomycin DCRH1T7 Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Dactinomycin DC191W0 Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Dactinomycin DCD9SER Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Dactinomycin DCVTZLI Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Dactinomycin DCL9SEI Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Dactinomycin DCXS3QO Dactinomycin Malignant melanoma (Cell Line: UACC62) [3]
Gefitinib + Dactinomycin DC40PR3 Dactinomycin Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Dactinomycin DCDGENV Dactinomycin Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Dactinomycin DCX00O2 Dactinomycin Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Dactinomycin DCD8PRJ Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Dactinomycin DCR7BXB Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Dactinomycin DC6E349 Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Dactinomycin DC579FP Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Dactinomycin DCWVN3U Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Dactinomycin DCX59FM Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Dactinomycin DC46KCT Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Dactinomycin DCMQDPJ Dactinomycin Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Dactinomycin DCZLV8N Dactinomycin Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Dactinomycin DC100Z8 Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + DFN-15 DCW48H1 DFN-15 Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + DFN-15 DCM8F6B DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Lapatinib DC5AWO7 Lapatinib Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Lapatinib DCBVIMM Lapatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Lapatinib DCJ2DIY Lapatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Lapatinib DCL2U68 Lapatinib Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Lapatinib DCLCMX6 Lapatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Lapatinib DC0UEVY Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Lapatinib DCPAMBN Lapatinib Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Lapatinib DCNR29C Lapatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Furazolidone DCXYQ7P Furazolidone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + PMID28460551-Compound-2 DCV32GF PMID28460551-Compound-2 Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + PMID28460551-Compound-2 DCQ47T2 PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + PMID28460551-Compound-2 DCR6ZTM PMID28460551-Compound-2 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + PMID28460551-Compound-2 DCC2Q28 PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + PMID28460551-Compound-2 DCLCECT PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + PMID28460551-Compound-2 DCR480O PMID28460551-Compound-2 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + PMID28460551-Compound-2 DCFG3I0 PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + PMID28460551-Compound-2 DCWZ3QE PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + PMID28460551-Compound-2 DCTI5ZC PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + PMID28460551-Compound-2 DCRFX41 PMID28460551-Compound-2 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + PMID28460551-Compound-2 DC0H8B2 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Crizotinib DC6H23R Crizotinib Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Crizotinib DCJ7MZE Crizotinib Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Crizotinib DCUUSGL Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Crizotinib DCN8KWT Crizotinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Crizotinib DCC9Y4G Crizotinib Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Crizotinib DCV47W2 Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Cyclophosphamide DC3TZAV Cyclophosphamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + LIAROZOLE DC6GU4B LIAROZOLE Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + LIAROZOLE DCFA9HE LIAROZOLE Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + LIAROZOLE DCU3BCP LIAROZOLE Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + LIAROZOLE DCM0S2P LIAROZOLE Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + LIAROZOLE DC5EUMN LIAROZOLE Glioma (Cell Line: SF-268) [3]
Gefitinib + LIAROZOLE DC4VJLX LIAROZOLE Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + LIAROZOLE DCTN1MI LIAROZOLE Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Methotrexate DCX2VUW Methotrexate Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + Methotrexate DCK8YK5 Methotrexate Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Methotrexate DCFKUIP Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Methotrexate DCYSTMC Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Methotrexate DC00TDD Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Methotrexate DCJ6ZRH Methotrexate Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Methotrexate DCQRZBI Methotrexate Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Dihydroergotamine DCMICZA Dihydroergotamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Miglustat DCK40AX Miglustat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Isoniazid DCW3V3U Isoniazid Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Isoniazid DCKD1Z2 Isoniazid Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Repaglinide DCWV2RS Repaglinide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Arsenic trioxide DC4NJ7B Arsenic trioxide Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Arsenic trioxide DCUBRGA Arsenic trioxide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Arsenic trioxide DC8QCHK Arsenic trioxide Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Vemurafenib DCY7823 Vemurafenib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Vemurafenib DCRYU44 Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Vemurafenib DCSXXIN Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Vemurafenib DCVVTAP Vemurafenib Glioma (Cell Line: SF-268) [3]
Gefitinib + Vemurafenib DCIKFQH Vemurafenib Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Anamorelin DCW53LP Anamorelin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Plicamycin DCUFMZ3 Plicamycin Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Plicamycin DC89OHM Plicamycin Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Plicamycin DCTUSDX Plicamycin Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Plicamycin DCQ8HXE Plicamycin Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Plicamycin DCTOIWA Plicamycin Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Plicamycin DCH8BFJ Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + Plicamycin DCZOTFR Plicamycin Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Plicamycin DC9KDW7 Plicamycin Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Plicamycin DCSX4NG Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Plicamycin DCILU4A Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Plicamycin DC4LNBP Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Gefitinib + Plicamycin DCOYZNF Plicamycin Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Plicamycin DCF8J0J Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Plicamycin DCF4218 Plicamycin Astrocytoma (Cell Line: U251) [3]
Gefitinib + Plicamycin DCKM9JR Plicamycin Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Plicamycin DCXQC4R Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Plicamycin DC37OR9 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Plicamycin DC6IFPI Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Plicamycin DCUU37D Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Plicamycin DCEOZLY Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Plicamycin DCXZF6G Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Plicamycin DCS785L Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Plicamycin DC18VHD Plicamycin Glioma (Cell Line: SF-539) [3]
Gefitinib + Plicamycin DCQH1E7 Plicamycin Glioma (Cell Line: SF-295) [3]
Gefitinib + Plicamycin DC8NLOD Plicamycin Glioma (Cell Line: SF-268) [3]
Gefitinib + Plicamycin DCHF8ER Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Plicamycin DCBR4DH Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Plicamycin DCBS1LJ Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Plicamycin DC4XTOW Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Plicamycin DCNJBKC Plicamycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Plicamycin DCGHE8T Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Plicamycin DCCPK3P Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Plicamycin DCITRJA Plicamycin Malignant melanoma (Cell Line: UACC62) [3]
Gefitinib + Plicamycin DCLOBCE Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Plicamycin DCAW2H7 Plicamycin Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Plicamycin DC4I84G Plicamycin Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Plicamycin DCFKP2A Plicamycin Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Plicamycin DC0KEXP Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Plicamycin DC1G4RC Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Plicamycin DCBRGBH Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Plicamycin DCWINL4 Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Plicamycin DCQSDVR Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Plicamycin DCGVS4K Plicamycin Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Plicamycin DCUTD31 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Nilotinib DCP4ZKD Nilotinib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Nilotinib DCR6NQY Nilotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Nilotinib DCX7C2V Nilotinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Nilotinib DCF7B1D Nilotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Nilotinib DCYAVXK Nilotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Nilotinib DCHXAP9 Nilotinib Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Nilotinib DCOS2X4 Nilotinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Thioguanine DC1O3X0 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Thioguanine DCRYUTV Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Thioguanine DCHQESV Thioguanine Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Thioguanine DC9IXWR Thioguanine Glioma (Cell Line: SF-268) [3]
Gefitinib + Thioguanine DCBHOQS Thioguanine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Thioguanine DCWP8CM Thioguanine Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Triapine DCMTH5D Triapine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Triapine DC4B246 Triapine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Acitretin DC8DJYE Acitretin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Pepstatin DC5IFN1 Pepstatin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + 10-hydroxycamptothecin DCDYPSE 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + 10-hydroxycamptothecin DC753LI 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + 10-hydroxycamptothecin DCVAFF2 10-hydroxycamptothecin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + 10-hydroxycamptothecin DCJX5VN 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + 10-hydroxycamptothecin DCUZS45 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + 10-hydroxycamptothecin DCFLDOU 10-hydroxycamptothecin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + 10-hydroxycamptothecin DCIJNGE 10-hydroxycamptothecin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + 10-hydroxycamptothecin DCF8CFQ 10-hydroxycamptothecin Glioma (Cell Line: SF-295) [3]
Gefitinib + 10-hydroxycamptothecin DCB0UE3 10-hydroxycamptothecin Glioma (Cell Line: SF-539) [3]
Gefitinib + 10-hydroxycamptothecin DC5093V 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + 10-hydroxycamptothecin DC9M17P 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + 10-hydroxycamptothecin DCF7SUR 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + 10-hydroxycamptothecin DC4CPHQ 10-hydroxycamptothecin Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + 10-hydroxycamptothecin DC4SS0O 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + 10-hydroxycamptothecin DCF11XV 10-hydroxycamptothecin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Topetecan DCWKMMC Topetecan Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Topetecan DCK99LA Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Topetecan DCXSUJF Topetecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Topetecan DCZH09I Topetecan High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Topetecan DCIDNER Topetecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Topetecan DCA1SJL Topetecan Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Topetecan DCGF2O8 Topetecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Amonafide DC47UBC Amonafide Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Amonafide DCPHWC7 Amonafide Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Amonafide DCPYZCK Amonafide Astrocytoma (Cell Line: U251) [3]
Gefitinib + Amonafide DCR47PP Amonafide Glioma (Cell Line: SF-268) [3]
Gefitinib + Amonafide DCJY49S Amonafide Glioma (Cell Line: SF-539) [3]
Gefitinib + Amonafide DCPY6AH Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Amonafide DCMB8GA Amonafide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Amonafide DC5GMYZ Amonafide Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Amonafide DC8QMPE Amonafide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Amonafide DC3H1XH Amonafide Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Amonafide DCB9USH Amonafide Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Amonafide DC85FF2 Amonafide Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Pralatrexate DCDI5KT Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Pralatrexate DCATZVT Pralatrexate Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Methylergonovine DC3W1C4 Methylergonovine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Palonosetron DCNMHRC Palonosetron Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Efavirenz DCR037R Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Terameprocol DCKNO50 Terameprocol Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Terameprocol DC230MQ Terameprocol Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Gefitinib + Terameprocol DCHNVJK Terameprocol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Terameprocol DCIW52Z Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Guanfacine DC0SWCW Guanfacine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + SCH 727965 DC8XHCY SCH 727965 Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + SCH 727965 DCWJHOH SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + SCH 727965 DCH7U1T SCH 727965 Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + SCH 727965 DCRKGEK SCH 727965 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + SCH 727965 DCFFHUQ SCH 727965 Astrocytoma (Cell Line: U251) [3]
Gefitinib + SCH 727965 DC72GHP SCH 727965 Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + SCH 727965 DCYYI8L SCH 727965 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + SCH 727965 DCJDQ21 SCH 727965 Melanoma (Cell Line: UACC-257) [3]
Gefitinib + SCH 727965 DCT8XBL SCH 727965 Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + SCH 727965 DCSGCJY SCH 727965 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Ifosfamide DCTR6GQ Ifosfamide Glioma (Cell Line: SF-268) [3]
Gefitinib + Carglumic acid DC4BZUF Carglumic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + K-134 DCAW5MC K-134 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Dexrazoxane DCYFIC6 Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Dexrazoxane DCN7LI4 Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Dexrazoxane DCPFXIQ Dexrazoxane Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Dexrazoxane DCJGKCL Dexrazoxane Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Dexrazoxane DCAH5E1 Dexrazoxane Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Dexrazoxane DC5HL48 Dexrazoxane Glioma (Cell Line: SF-268) [3]
Gefitinib + Dexrazoxane DCGE1UM Dexrazoxane Glioma (Cell Line: SF-539) [3]
Gefitinib + Dexrazoxane DCHVN40 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Dexrazoxane DCFKSO2 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Dexrazoxane DCJQMJ0 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Dexrazoxane DCT8NGX Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Dexrazoxane DCF5YHN Dexrazoxane Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Dexrazoxane DCLKMA9 Dexrazoxane Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Dexrazoxane DC0GS3G Dexrazoxane Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Dexrazoxane DCB8VHI Dexrazoxane Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Dexrazoxane DCFZ1D0 Dexrazoxane Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Dexrazoxane DCTNANE Dexrazoxane Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Dexrazoxane DCDWB8I Dexrazoxane Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Memantine DCD7TCO Memantine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Docetaxel DCTAROO Docetaxel Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Docetaxel DCQ2E8C Docetaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Docetaxel DCDASEZ Docetaxel Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Docetaxel DC8ZSCE Docetaxel Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Docetaxel DC40O27 Docetaxel Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Docetaxel DC531EA Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Docetaxel DC5PNQN Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Docetaxel DCF14U9 Docetaxel Astrocytoma (Cell Line: U251) [3]
Gefitinib + Docetaxel DCCPR4O Docetaxel Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Docetaxel DCPCFSN Docetaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Docetaxel DCCA201 Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Docetaxel DCCAPAF Docetaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Docetaxel DC9H9AF Docetaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Docetaxel DCZ9NHW Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Docetaxel DC5CEYN Docetaxel Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Docetaxel DCWFUVY Docetaxel Glioma (Cell Line: SF-268) [3]
Gefitinib + Docetaxel DCQKRDK Docetaxel Glioma (Cell Line: SF-295) [3]
Gefitinib + Docetaxel DCAF889 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Docetaxel DC5I2KF Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Docetaxel DCLF9CG Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Docetaxel DCA8H3K Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Docetaxel DCNGDNZ Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Docetaxel DCDGTNF Docetaxel Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Docetaxel DCV04ML Docetaxel Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Docetaxel DCLWVGK Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Docetaxel DC62LJV Docetaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Docetaxel DC8RBHA Docetaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Docetaxel DC1HWTF Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Docetaxel DCRFWGG Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Docetaxel DCYOPCJ Docetaxel Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Raloxifene DC99M1T Raloxifene Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + LY03004 DC0JQ6I LY03004 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Galantamine DC7N167 Galantamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Sulfinpyrazone DCA3IET Sulfinpyrazone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Pazopanib DCE8HQP Pazopanib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Daidzin DCOES54 Daidzin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Bendamustine hydrochloride DCNESQ3 Bendamustine hydrochloride Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Bendamustine hydrochloride DCYF2HB Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Bendamustine hydrochloride DCFPASH Bendamustine hydrochloride Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Bendamustine hydrochloride DCODQEF Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Bendamustine hydrochloride DCAXV1D Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Bendamustine hydrochloride DCYDKII Bendamustine hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Bendamustine hydrochloride DCZ6CX4 Bendamustine hydrochloride Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Bendamustine hydrochloride DCLYOL6 Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Bendamustine hydrochloride DC5SCKR Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Bendamustine hydrochloride DC1S8EJ Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Bendamustine hydrochloride DCIZTYO Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Bendamustine hydrochloride DCVAW8X Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Bendamustine hydrochloride DCZK1UO Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Bendamustine hydrochloride DCS54LL Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Bendamustine hydrochloride DCXTKMZ Bendamustine hydrochloride Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Bendamustine hydrochloride DCIKOJR Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Bendamustine hydrochloride DCMD2ZI Bendamustine hydrochloride Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Bendamustine hydrochloride DCPRFL5 Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Bendamustine hydrochloride DC8DF14 Bendamustine hydrochloride Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Bendamustine hydrochloride DC25F07 Bendamustine hydrochloride Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Bendamustine hydrochloride DC7VQH9 Bendamustine hydrochloride Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Bendamustine hydrochloride DCU31IS Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Bendamustine hydrochloride DCVS8RN Bendamustine hydrochloride Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Fluspirilene DC74C1H Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + VR-776 DC6J8O4 VR-776 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Trifluridine DCQGY3B Trifluridine Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Trifluridine DCTIFG1 Trifluridine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Trifluridine DCP3C5W Trifluridine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Trifluridine DCHZ8FH Trifluridine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Trifluridine DCUE28R Trifluridine Glioma (Cell Line: SF-539) [3]
Gefitinib + Trifluridine DCZNDGQ Trifluridine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Trifluridine DCAPY99 Trifluridine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Trifluridine DCSRF4B Trifluridine Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + WAY-100635 DCB4FFJ WAY-100635 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Ciprofibrate DCTE2UO Ciprofibrate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Sirolimus DCD2KPZ Sirolimus Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Sirolimus DCVBPGY Sirolimus Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Sirolimus DCCIEJ0 Sirolimus Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Sirolimus DCV7YR5 Sirolimus Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Sirolimus DC0Z9JC Sirolimus Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Sirolimus DCOB0HA Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Sirolimus DCLJ3AG Sirolimus Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Sirolimus DC31ULJ Sirolimus Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mifepristone DCWH9M9 Mifepristone Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Gefitinib + Letrozole DCTOG6H Letrozole Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Letrozole DCON3LT Letrozole Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Mitomycin DCAGBD3 Mitomycin Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Mitomycin DCIDF9C Mitomycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Mitomycin DCK65BG Mitomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Mitomycin DCM3550 Mitomycin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Mitomycin DCUEVH5 Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Mitomycin DCQEJUP Mitomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Mitomycin DCZATA3 Mitomycin Glioma (Cell Line: SF-268) [3]
Gefitinib + Mitomycin DCKBPEM Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Mitomycin DC37BOK Mitomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Mitomycin DCTMDD2 Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Mitomycin DC45TPD Mitomycin Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Mitomycin DC7HJX4 Mitomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mitomycin DC9DGEC Mitomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Mitomycin DCMG1AY Mitomycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Mitomycin DC2E9V2 Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Mitomycin DC491NZ Mitomycin Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + SY-1425 DC47O85 SY-1425 Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + SY-1425 DCSC8VK SY-1425 Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + SY-1425 DC9A8E5 SY-1425 Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + SY-1425 DCHM3OE SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + SY-1425 DCXVL5D SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + SY-1425 DCT6Y0B SY-1425 Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + SY-1425 DCISVSX SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + SY-1425 DCBC21J SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Clopidogrel DCOMDF3 Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Uracil mustard DCO9SRB Uracil mustard Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Uracil mustard DCI12KL Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Uracil mustard DCKLGJI Uracil mustard Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Uracil mustard DCEJ1BF Uracil mustard Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Uracil mustard DCQVE4Q Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Uracil mustard DCI332T Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Uracil mustard DC1VFH2 Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Uracil mustard DCTM0NU Uracil mustard Astrocytoma (Cell Line: U251) [3]
Gefitinib + Uracil mustard DC6QE7C Uracil mustard Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Uracil mustard DC7L674 Uracil mustard Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Uracil mustard DCJW34S Uracil mustard Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + Uracil mustard DCELVZB Uracil mustard Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Uracil mustard DCKUF0S Uracil mustard Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Uracil mustard DC25QYN Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Uracil mustard DCU0LI5 Uracil mustard Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Uracil mustard DCXEGJW Uracil mustard Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Uracil mustard DCCW0H5 Uracil mustard Glioma (Cell Line: SF-295) [3]
Gefitinib + Uracil mustard DCMODLL Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Uracil mustard DCI0C2T Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Uracil mustard DCCWRUE Uracil mustard Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Uracil mustard DCZXW9K Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Uracil mustard DC74O69 Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Uracil mustard DC16VR9 Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Uracil mustard DCZP4HM Uracil mustard Malignant melanoma (Cell Line: UACC62) [3]
Gefitinib + Uracil mustard DC80C21 Uracil mustard Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Uracil mustard DCUFGPA Uracil mustard Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Uracil mustard DC20TOV Uracil mustard Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Uracil mustard DCBY87K Uracil mustard Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Uracil mustard DCZXPS9 Uracil mustard Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Uracil mustard DCVJFE0 Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Uracil mustard DCD5MI5 Uracil mustard Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Uracil mustard DCIVUF3 Uracil mustard Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Uracil mustard DC3YLX6 Uracil mustard Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Pentamidine DC88D6J Pentamidine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Procarbazine DCO20M1 Procarbazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Vincristine DCHXHGU Vincristine Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Vincristine DCBFMM5 Vincristine Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Vincristine DCNUET5 Vincristine Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Vincristine DCWVYE6 Vincristine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Vincristine DCH78SP Vincristine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Vincristine DCJI3VN Vincristine Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Vincristine DC6QTMH Vincristine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Vincristine DCOTSD0 Vincristine Glioma (Cell Line: SF-295) [3]
Gefitinib + Vincristine DCVMNUI Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Vincristine DCA6XXA Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Vincristine DCYL7ET Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Vincristine DC5CNPQ Vincristine Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Vincristine DCC5HEN Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Vincristine DC3GBRB Vincristine Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Vincristine DCO1YE0 Vincristine Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Vincristine DCMCWM3 Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Vincristine DCPVUBY Vincristine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Vincristine DC4LX6M Vincristine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Vincristine DC3NYG2 Vincristine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Vincristine DCRW7R9 Vincristine Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Vincristine DCSTU4J Vincristine Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Arfolitixorin DCB4R3K Arfolitixorin Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Arfolitixorin DCWX9V1 Arfolitixorin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Arfolitixorin DC7ZH06 Arfolitixorin Glioma (Cell Line: SF-268) [3]
Gefitinib + Arfolitixorin DCH72KU Arfolitixorin Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Arfolitixorin DCUHP9A Arfolitixorin Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Arfolitixorin DCQ7HFW Arfolitixorin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Arfolitixorin DCADS4J Arfolitixorin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Arfolitixorin DC0UHDB Arfolitixorin Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + BIO-300 DCCPUIW BIO-300 Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + BIO-300 DC8GV4Z BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + BIO-300 DCALTNT BIO-300 Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + BIO-300 DCWY00V BIO-300 Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + BIO-300 DCG5D82 BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + BIO-300 DCJDY0F BIO-300 Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + BIO-300 DCA0CUN BIO-300 Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + BIO-300 DC8W0OK BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + BIO-300 DC20F2D BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + BIO-300 DCSSCQ8 BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + BIO-300 DCIZR00 BIO-300 Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + BIO-300 DCLKGMZ BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + BIO-300 DC5A000 BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + BIO-300 DCL1BE3 BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + BIO-300 DCQN90O BIO-300 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + BIO-300 DCZ9K1L BIO-300 Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + BIO-300 DCLCBOA BIO-300 Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + BIO-300 DCZQMPC BIO-300 Glioma (Cell Line: SF-268) [3]
Gefitinib + BIO-300 DCTGW88 BIO-300 Glioma (Cell Line: SF-539) [3]
Gefitinib + BIO-300 DCH93D2 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + BIO-300 DC2SMR9 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + BIO-300 DCYL39W BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + BIO-300 DCYLKKY BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + BIO-300 DCH1CQ6 BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + BIO-300 DCE962A BIO-300 Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + BIO-300 DCK5HRR BIO-300 Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + BIO-300 DCMT5ED BIO-300 Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + BIO-300 DCWZGAN BIO-300 Melanoma (Cell Line: UACC-257) [3]
Gefitinib + BIO-300 DC7UE7G BIO-300 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + BIO-300 DCMJD40 BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + BIO-300 DCVRKAH BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + BIO-300 DCJQMXN BIO-300 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + BIO-300 DCKLSEW BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + BIO-300 DC6LK6K BIO-300 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + BIO-300 DC06CNG BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + BIO-300 DC4693A BIO-300 Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + BIO-300 DCAI3GK BIO-300 Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + BIO-300 DCVVQ1V BIO-300 Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + PF-02545920 DCGDRMN PF-02545920 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Trifluoperazine DCW76ZK Trifluoperazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Altretamine DCV3Y69 Altretamine Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Altretamine DCNRP4I Altretamine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Altretamine DCUR09W Altretamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Oseltamivir DC6DH8F Oseltamivir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + TEM DCWJMKA TEM Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + TEM DCB9KXT TEM Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + JNK-IN-8 DCWFS9C JNK-IN-8 Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + JNK-IN-8 DC3YGSF JNK-IN-8 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Idarubicin DCMIVGE Idarubicin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Idarubicin DCU9MGE Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Gefitinib + Imatinib DCM1VGD Imatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Imatinib DC0I4BT Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Imatinib DCDB6PV Imatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Imatinib DC77KMM Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Imatinib DC9K7IM Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Imatinib DC3RA6K Imatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Imatinib DC66PA5 Imatinib Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Bleomycin DCY1E51 Bleomycin Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Bleomycin DCWI2LB Bleomycin Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Bleomycin DC6W7EY Bleomycin Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Bleomycin DCBSMIW Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + Bleomycin DCU8Q6E Bleomycin Adenocarcinoma (Cell Line: HCT116) [3]
Gefitinib + Bleomycin DCGAO0P Bleomycin Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Bleomycin DCTQXPG Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Bleomycin DCWHCNF Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Bleomycin DCV6PJO Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Bleomycin DCGLNOF Bleomycin Astrocytoma (Cell Line: U251) [3]
Gefitinib + Bleomycin DCNSAZL Bleomycin Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Bleomycin DCOZFXQ Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Bleomycin DC9TS89 Bleomycin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Bleomycin DC8V7MP Bleomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Bleomycin DC8XBS0 Bleomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Bleomycin DCRXOWO Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Bleomycin DCQXVDQ Bleomycin Glioma (Cell Line: SF-268) [3]
Gefitinib + Bleomycin DC8C33C Bleomycin Glioma (Cell Line: SF-295) [3]
Gefitinib + Bleomycin DCIKIO7 Bleomycin Glioma (Cell Line: SF-539) [3]
Gefitinib + Bleomycin DCIRMB9 Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Bleomycin DCOZPVF Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Bleomycin DC1PN9Q Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Bleomycin DCLQVQJ Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Bleomycin DCUCWZB Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Gefitinib + Bleomycin DCKUVDE Bleomycin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Bleomycin DCTT71U Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Bleomycin DCLTHYZ Bleomycin Melanoma (Cell Line: SK-MEL-2) [3]
Gefitinib + Bleomycin DC0UU7L Bleomycin Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Bleomycin DCSOTIW Bleomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Bleomycin DC7J4C3 Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Bleomycin DCULSIG Bleomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Bleomycin DCSQXY3 Bleomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Bleomycin DCY227G Bleomycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Bleomycin DC4AT0C Bleomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Bleomycin DC4I7JE Bleomycin Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Bleomycin DCJSKY7 Bleomycin Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Bortezomib DCY3Y6T Bortezomib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Bortezomib DCHPNX9 Bortezomib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Bortezomib DCDO39L Bortezomib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Bortezomib DCNYG76 Bortezomib Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Anastrozole DC31UBG Anastrozole Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Anastrozole DCFRGJ3 Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Anastrozole DCNCFW6 Anastrozole Glioma (Cell Line: SF-295) [3]
Gefitinib + Anastrozole DC5ODO0 Anastrozole Glioma (Cell Line: SF-268) [3]
Gefitinib + Anastrozole DC6WTY6 Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Anastrozole DCXR1QY Anastrozole Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Anastrozole DC0C47R Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Anastrozole DCNO6NE Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [3]
Gefitinib + Anastrozole DC05NSZ Anastrozole Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Anastrozole DCXZ73Z Anastrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Anastrozole DC270YW Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Anastrozole DCISCHY Anastrozole Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Anastrozole DCQWPKJ Anastrozole Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Dacarbazine DC926OV Dacarbazine Amelanotic melanoma (Cell Line: M14) [3]
Gefitinib + Dacarbazine DCC0ITW Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Dacarbazine DCC5GAT Dacarbazine Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Dacarbazine DC8P9OX Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Dacarbazine DCR5SK9 Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Dacarbazine DCFOW61 Dacarbazine Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Dacarbazine DC7B4JW Dacarbazine Malignant melanoma (Cell Line: UACC62) [3]
Gefitinib + Dacarbazine DCU9A3U Dacarbazine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Dacarbazine DCDP5LO Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Tropisetron DCF3AHY Tropisetron Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Valrubicin DCU6RG3 Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Topotecan DCWQBCG Topotecan Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Topotecan DC28B19 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Topotecan DCLL989 Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Gefitinib + Topotecan DCFC9RK Topotecan Glioma (Cell Line: SF-268) [3]
Gefitinib + Topotecan DC1GVT3 Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Gefitinib + Topotecan DCLDHBI Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Topotecan DC4A1AD Topotecan Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Topotecan DCKB3V5 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Topotecan DC4HSLM Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Topotecan DCPRZC4 Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Topotecan DCRQ68K Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Topotecan DCKM2IX Topotecan Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Trimethobenzamide DCP7D58 Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Maprotiline DCBMBAR Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Eptifibatide DC6SQKT Eptifibatide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Acetohexamide DC0PSYH Acetohexamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Cisplatin DC6SWKQ Cisplatin Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Cisplatin DCEXNCP Cisplatin Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Cisplatin DCK2LBG Cisplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Cisplatin DC55LDC Cisplatin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Cisplatin DCVBLTH Cisplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Chlorambucil DCQF28F Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Chlorambucil DCTQJVO Chlorambucil Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Chlorambucil DCWGZHC Chlorambucil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Chlorambucil DCNCODO Chlorambucil Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Chlorambucil DCILG8G Chlorambucil Melanoma (Cell Line: UACC-257) [3]
Gefitinib + Chlorambucil DCOGGUP Chlorambucil Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Bumetanide DCMBDD9 Bumetanide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Sorafenib DC8WPJF Sorafenib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Sorafenib DCS5AU4 Sorafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Sorafenib DCGQGRK Sorafenib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Sorafenib DCRCPAI Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Sorafenib DCKF6R2 Sorafenib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Sorafenib DC1ITE1 Sorafenib Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Desoxycorticosterone pivalate DC7FIQJ Desoxycorticosterone pivalate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + ER819762 DCQY2CK ER819762 Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + ER819762 DCCBUFD ER819762 Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + ER819762 DCT99AL ER819762 Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + ER819762 DC24JUN ER819762 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + ER819762 DCDQ6R6 ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + ER819762 DC1YKGF ER819762 Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Hyodeoxycholic acid DCW96LK Hyodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Romidepsin DC9YNPD Romidepsin Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Romidepsin DCK9YBX Romidepsin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Romidepsin DCWYOXS Romidepsin Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Romidepsin DCE3Q0X Romidepsin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Gefitinib + Romidepsin DC2RU83 Romidepsin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Romidepsin DCD03J7 Romidepsin Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Romidepsin DC0AV23 Romidepsin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Romidepsin DCMTIKZ Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Romidepsin DC4SLYK Romidepsin Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Romidepsin DC710JB Romidepsin Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Romidepsin DCMAZY7 Romidepsin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Romidepsin DCV82W3 Romidepsin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Romidepsin DCR7SCQ Romidepsin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Romidepsin DC2OZMM Romidepsin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Romidepsin DC30M0P Romidepsin Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Azacitidine DCI72KH Azacitidine Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Azacitidine DCVOEDM Azacitidine Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Azacitidine DC1I4T3 Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Azacitidine DCUJLM2 Azacitidine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Azacitidine DCI0KUK Azacitidine Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Azacitidine DCBRMR0 Azacitidine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Azacitidine DC98NHM Azacitidine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Azacitidine DCTDIUD Azacitidine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Azacitidine DC83XIY Azacitidine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Azacitidine DCAMQ24 Azacitidine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Pomalidomide DCQ383X Pomalidomide Glioma (Cell Line: SF-268) [3]
Gefitinib + Pomalidomide DCBTDDE Pomalidomide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Pomalidomide DC6W5CB Pomalidomide Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Vinflunine DCURV9U Vinflunine Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Vinflunine DCQ3UU0 Vinflunine Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Vinflunine DCHWUK3 Vinflunine Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Vinflunine DCG45GL Vinflunine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Vinflunine DCG7N1H Vinflunine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Vinflunine DCYXOXJ Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Vinflunine DCQC7IE Vinflunine Glioma (Cell Line: SF-268) [3]
Gefitinib + Vinflunine DCUB0C9 Vinflunine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Vinflunine DCMRXB6 Vinflunine Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Vinflunine DC04003 Vinflunine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Vinflunine DCDKD9W Vinflunine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mercaptopurine DCD5NRO Mercaptopurine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mycophenolic acid DC8IOZR Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Mepacrine DCOFUUH Mepacrine Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Mepacrine DC6MWLG Mepacrine Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Gefitinib + Mepacrine DCPOR6R Mepacrine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mepacrine DCCDHY2 Mepacrine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Mepacrine DCPIVTI Mepacrine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Gefitinib + Taxol DCMU31W Taxol Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Taxol DC2LB27 Taxol Adenocarcinoma (Cell Line: NCIH23) [3]
Gefitinib + Taxol DCXRCQP Taxol Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Taxol DCHSVM0 Taxol Astrocytoma (Cell Line: U251) [3]
Gefitinib + Taxol DC79M7N Taxol Astrocytoma (Cell Line: SNB-19) [3]
Gefitinib + Taxol DC99NY1 Taxol Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Taxol DC9MBA7 Taxol Glioma (Cell Line: SF-295) [3]
Gefitinib + Taxol DCP80Y8 Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Gefitinib + Taxol DCJ7GTZ Taxol Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Taxol DC77632 Taxol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Taxol DCRJD8Z Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Mefloquine DCGA7HL Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Lacosamide DC1NNE9 Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Vinpocetine DCQU312 Vinpocetine Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Gefitinib + Fludarabine DCBRZ6V Fludarabine Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Fludarabine DC2FLGY Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Fludarabine DC63JNR Fludarabine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Fludarabine DC4YBGD Fludarabine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Fludarabine DCSQZHO Fludarabine Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Nabilone DCQ41MF Nabilone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Silver sulfadiazine DC6PE0F Silver sulfadiazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + PMID28870136-Compound-43 DC6OWOM PMID28870136-Compound-43 Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + PMID28870136-Compound-43 DCFO8IG PMID28870136-Compound-43 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + PMID28870136-Compound-43 DCZQD8S PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + PMID28870136-Compound-43 DCYYTE9 PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + PMID28870136-Compound-43 DC0JPF3 PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + PMID28870136-Compound-43 DC8LPDO PMID28870136-Compound-43 Glioma (Cell Line: SF-539) [3]
Gefitinib + PMID28870136-Compound-43 DCR6FBB PMID28870136-Compound-43 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + PMID28870136-Compound-43 DCZHFAD PMID28870136-Compound-43 Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + FORMESTANE DCKQYT4 FORMESTANE Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + FORMESTANE DCXM1BM FORMESTANE Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + FORMESTANE DCXVOAQ FORMESTANE Adenocarcinoma (Cell Line: HCC-2998) [3]
Gefitinib + FORMESTANE DC0KV9D FORMESTANE Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + FORMESTANE DCW4RX1 FORMESTANE Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Gefitinib + FORMESTANE DCAC4BQ FORMESTANE Glioma (Cell Line: SF-268) [3]
Gefitinib + FORMESTANE DCOZ37C FORMESTANE Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Gefitinib + Vorinostat DCJJDEO Vorinostat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DCQWQCA Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DC2MDAW Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DCKNKCZ Aminolevulinic Acid Hydrochloride Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DCZTPS3 Aminolevulinic Acid Hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DC5ZEIT Aminolevulinic Acid Hydrochloride Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DC42723 Aminolevulinic Acid Hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DC2O9UP Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DCIQD73 Aminolevulinic Acid Hydrochloride Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Aminolevulinic Acid Hydrochloride DC98M4B Aminolevulinic Acid Hydrochloride Renal cell carcinoma (Cell Line: UO-31) [3]
Gefitinib + Estramustine DCCCCXW Estramustine Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Estramustine DC4AOPY Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Estramustine DCOLTAN Estramustine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Digitoxin DCQ4BWQ Digitoxin Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Digitoxin DCNN93R Digitoxin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Digitoxin DCIGSTW Digitoxin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Gefitinib + Digitoxin DC9AVZT Digitoxin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Gefitinib + Digitoxin DCUV21H Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Gefitinib + Digitoxin DCI0YJ1 Digitoxin Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Digitoxin DCB1JS7 Digitoxin Glioma (Cell Line: SF-268) [3]
Gefitinib + Digitoxin DC53Y8T Digitoxin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Digitoxin DCHXZL7 Digitoxin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Gefitinib + Digitoxin DCX38RK Digitoxin Melanoma (Cell Line: MALME-3M) [3]
Gefitinib + Digitoxin DCZB1DC Digitoxin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Digitoxin DCHNTDG Digitoxin Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Digitoxin DC642D1 Digitoxin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Gefitinib + Cerivastatin DCC3XUE Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Busulfan DCZ0S12 Busulfan Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Busulfan DC57FWB Busulfan Adenocarcinoma (Cell Line: SW-620) [3]
Gefitinib + Busulfan DCTYGHA Busulfan Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Gefitinib + Busulfan DCDLXMH Busulfan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Busulfan DCE1JG3 Busulfan Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Busulfan DCUNAAH Busulfan Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Gefitinib + Busulfan DCL223O Busulfan Chronic myelogenous leukemia (Cell Line: K-562) [3]
Gefitinib + Busulfan DCWN64S Busulfan Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Busulfan DCSTLD3 Busulfan High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Busulfan DCZMPAA Busulfan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Busulfan DCFWSYF Busulfan Renal cell carcinoma (Cell Line: SN12C) [3]
Gefitinib + Aciclovir DCPTZA6 Aciclovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Raltegravir DC757EH Raltegravir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Dasatinib DCIFGH4 Dasatinib Adenocarcinoma (Cell Line: DU-145) [3]
Gefitinib + Dasatinib DCNE3EI Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Gefitinib + Dasatinib DC18K0Q Dasatinib Adenocarcinoma (Cell Line: A549) [3]
Gefitinib + Dasatinib DCS2DVG Dasatinib Adenocarcinoma (Cell Line: HCT-15) [3]
Gefitinib + Dasatinib DCR2GD6 Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Dasatinib DCZD3G4 Dasatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Gefitinib + Dasatinib DC17YF1 Dasatinib Glioblastoma (Cell Line: SNB-75) [3]
Gefitinib + Dasatinib DCP1MR2 Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Gefitinib + Dasatinib DC4YOZ1 Dasatinib Lung adenocarcinoma (Cell Line: EKVX) [3]
Gefitinib + Dasatinib DC7RZFZ Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Gefitinib + Dasatinib DCTVMB0 Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Gefitinib + Dasatinib DCD5HNV Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Gefitinib + Dasatinib DCLCIF6 Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gefitinib + Dasatinib DC3Q4WL Dasatinib Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Cytarabine DCCGZ0O Cytarabine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Cilostazol DCWOV5U Cilostazol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Mechlorethamine DCWUL9P Mechlorethamine Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Mechlorethamine DCTNAE6 Mechlorethamine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Pentostatin DC0TEA4 Pentostatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Dactinomycin DCOCZA2 Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Dactinomycin DCZVP6W Dactinomycin Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + Dactinomycin DCKLLD9 Dactinomycin Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Dactinomycin DCJ60LW Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Dactinomycin DCAIFIO Dactinomycin Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Dactinomycin DCNVGBP Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Dactinomycin DCGNPVV Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gefitinib + Dactinomycin DCP78ZD Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Lapatinib DCQKB14 Lapatinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + PMID28460551-Compound-2 DC4S898 PMID28460551-Compound-2 Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Crizotinib DCZDQJK Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + LIAROZOLE DCU90U8 LIAROZOLE Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Methotrexate DCJT2HC Methotrexate Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Methotrexate DC5K6ZU Methotrexate Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Arsenic trioxide DC41P1H Arsenic trioxide Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Arsenic trioxide DCMTJ4S Arsenic trioxide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gefitinib + Plicamycin DCCVA90 Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Plicamycin DCXSPF3 Plicamycin Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + Plicamycin DC24KON Plicamycin Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Plicamycin DC0C9PW Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Plicamycin DC74WRB Plicamycin Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Plicamycin DC0VK6L Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gefitinib + Plicamycin DC85S88 Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Plicamycin DCD12LA Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Nilotinib DCCUT6E Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Thioguanine DCWTR6F Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Thioguanine DCPUEZY Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + 10-hydroxycamptothecin DCFZC9V 10-hydroxycamptothecin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + 10-hydroxycamptothecin DCYZHMV 10-hydroxycamptothecin Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Amonafide DCWA5N2 Amonafide Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Amonafide DCAG87I Amonafide Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Amonafide DC0RAGL Amonafide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Terameprocol DCOMPEV Terameprocol Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Terameprocol DC2DBFO Terameprocol Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + SCH 727965 DCBGK7G SCH 727965 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + SCH 727965 DC5DTTN SCH 727965 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Dexrazoxane DCN8F6Y Dexrazoxane Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Dexrazoxane DC3UO77 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Docetaxel DCAB6VU Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Raloxifene DCGCXPP Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Bendamustine hydrochloride DCSHCJQ Bendamustine hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Bendamustine hydrochloride DCNCU2I Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Bendamustine hydrochloride DC53Z9K Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Trifluridine DCO30JH Trifluridine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Sirolimus DC5ZN0Z Sirolimus Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Mitomycin DCJIAFS Mitomycin Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + Mitomycin DCYQ68A Mitomycin Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Mitomycin DCKVXLO Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Mitomycin DC7C1O3 Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Uracil mustard DCH3PRA Uracil mustard Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Uracil mustard DCU3LF0 Uracil mustard Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Vincristine DCJZ96R Vincristine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Arfolitixorin DCRF195 Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Arfolitixorin DC6ABJR Arfolitixorin Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + BIO-300 DC8BHAK BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + BIO-300 DCVRWVX BIO-300 Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + BIO-300 DCPGUGI BIO-300 Carcinoma (Cell Line: MCF7) [4]
Gefitinib + BIO-300 DC7Y74W BIO-300 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + BIO-300 DCI2DVP BIO-300 Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + BIO-300 DCBLP2G BIO-300 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + BIO-300 DCU4C5Q BIO-300 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gefitinib + Bleomycin DCWUWTC Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Bleomycin DCJ3Y7H Bleomycin Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Bleomycin DCZ2ZDC Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Bleomycin DCRU2CF Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Anastrozole DCYBCDH Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Anastrozole DCQ7SCS Anastrozole Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Dacarbazine DCFKQ5B Dacarbazine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Topotecan DCRRP41 Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Topotecan DC6T4MD Topotecan Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Topotecan DC540ZY Topotecan Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Topotecan DCWDY5M Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Chlorambucil DCK5ED9 Chlorambucil Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Chlorambucil DCTRSJ5 Chlorambucil Invasive ductal carcinoma (Cell Line: BT-549) [4]
Gefitinib + Romidepsin DCTU0AP Romidepsin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Gefitinib + Vinflunine DCD9NY3 Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Mercaptopurine DCIWSJB Mercaptopurine Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Mepacrine DCSVF0O Mepacrine Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Taxol DCDB76A Taxol Carcinoma (Cell Line: RXF 393) [4]
Gefitinib + Taxol DCWNTDI Taxol Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Fludarabine DCAWUIS Fludarabine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + PMID28870136-Compound-43 DCVFHGJ PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Aminolevulinic Acid Hydrochloride DC1ATEP Aminolevulinic Acid Hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [4]
Gefitinib + Digitoxin DCK35F4 Digitoxin Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Busulfan DCTNYCT Busulfan Carcinoma (Cell Line: MCF7) [4]
Gefitinib + Busulfan DC7URS0 Busulfan Colon adenocarcinoma (Cell Line: COLO 205) [4]
Gefitinib + Busulfan DCRUPJM Busulfan Colon carcinoma (Cell Line: KM12) [4]
Gefitinib + Busulfan DC5UX58 Busulfan Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Gefitinib + Dasatinib DCM7NBN Dasatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Ginsenoside Rb1 + Gefitinib DCS7EOX Ginsenoside Rb1 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
GYKI-52466 + Gefitinib DCFJ6O5 GYKI-52466 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Hydralazine + Gefitinib DCPWJI0 Hydralazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ibutilide + Gefitinib DCV76E3 Ibutilide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Idarubicin + Gefitinib DCCW12N Idarubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
IMD-0354 + Gefitinib DCXKBAU IMD-0354 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Indazole derivative 5 + Gefitinib DCLZ6SE Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Indazole derivative 5 + Gefitinib DCAT4E0 Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Indazole derivative 5 + Gefitinib DCOJU35 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Indazole derivative 5 + Gefitinib DCFAVND Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Indazole derivative 5 + Gefitinib DCFMSEH Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: A498) [3]
Indazole derivative 5 + Gefitinib DC6NHLR Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Indazole derivative 5 + Gefitinib DCNDDDM Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Indazole derivative 5 + Gefitinib DCVVSC9 Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Indazole derivative 5 + Gefitinib DC4F0SZ Indazole derivative 5 Carcinoma (Cell Line: MCF7) [4]
Indazole derivative 5 + Gefitinib DCN312B Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Indazole derivative 5 + Gefitinib DC2UBFG Indazole derivative 5 Adenocarcinoma (Cell Line: A549) [5]
Indazole derivative 5 + Gefitinib DCGEL7L Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [5]
Indazole derivative 5 + Gefitinib DCIH8W8 Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [5]
Indazole derivative 5 + Gefitinib DCFGCNS Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Indazole derivative 5 + Gefitinib DC6U6YN Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Indazole derivative 5 + Gefitinib DC4MJKQ Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [5]
Indazole derivative 5 + Gefitinib DCOZK7B Indazole derivative 5 Lung adenocarcinoma (Cell Line: EKVX) [5]
Indazole derivative 5 + Gefitinib DC5K9RP Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Indazole derivative 5 + Gefitinib DCHGM7H Indazole derivative 5 Melanoma (Cell Line: UACC-257) [5]
Indazole derivative 5 + Gefitinib DCANLNT Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [5]
Indazole derivative 5 + Gefitinib DCY4YE5 Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Indazole derivative 5 + Gefitinib DCK4N64 Indazole derivative 5 Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Indazole derivative 5 + Gefitinib DCIM6GE Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Isosorbide dinitrate + Gefitinib DC6ILB9 Isosorbide dinitrate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
IT-141 + Gefitinib DCGO0O9 IT-141 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
L-165041 + Gefitinib DCBT09S L-165041 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lacosamide + Gefitinib DCK8QKG Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lefaxin + Gefitinib DCC6TN4 Lefaxin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lenalidomide + Gefitinib DCKLS66 Lenalidomide Anaplastic large cell lymphoma (Cell Line: SR) [3]
Lenalidomide + Gefitinib DC9WX1K Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Lenalidomide + Gefitinib DCZXT06 Lenalidomide Glioma (Cell Line: SF-539) [3]
Lenalidomide + Gefitinib DCVOLWR Lenalidomide Adenocarcinoma (Cell Line: HT29) [5]
Loperamide + Gefitinib DC9AFIS Loperamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Maprotiline + Gefitinib DCG0TCL Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Maraviroc + Gefitinib DC27S4C Maraviroc Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mebendazole + Gefitinib DCZP3LW Mebendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mebendazole + Gefitinib DC56O3E Mebendazole Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Mebutamate + Gefitinib DCWNQI7 Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mecamylamine + Gefitinib DCX8TNN Mecamylamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mesalazine + Gefitinib DCDF59N Mesalazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Metaxalone + Gefitinib DCSWPO4 Metaxalone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Metformin + Gefitinib DC1TQFZ Metformin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Methocarbamol + Gefitinib DC9GMB2 Methocarbamol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Methotrexate + Gefitinib DCSA7GH Methotrexate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Moricizine + Gefitinib DCITU68 Moricizine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Naltrexone + Gefitinib DCY17NG Naltrexone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Niclosamide + Gefitinib DCDLKMC Niclosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Nitisinone + Gefitinib DCVBGCM Nitisinone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Nitrosoglutathione + Gefitinib DC5IFO4 Nitrosoglutathione Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Oxandrolone + Gefitinib DCY7666 Oxandrolone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Oxyphenbutazone + Gefitinib DC1PWKM Oxyphenbutazone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pamidronate + Gefitinib DCVP4WD Pamidronate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PD-0325901 + Gefitinib DCCCPG1 PD-0325901 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PD-0325901 + Gefitinib DCJY4RK PD-0325901 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PF-04691502 + Gefitinib DCB1USU PF-04691502 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
PF-04691502 + Gefitinib DC1GLS3 PF-04691502 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
PFK-158 + Gefitinib DC91BM2 PFK-158 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PHA-739358 + Gefitinib DCGQSI1 PHA-739358 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Phensuximide + Gefitinib DC3072W Phensuximide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Picoplatin + Gefitinib DC0GHA7 Picoplatin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pizotyline + Gefitinib DC2DB9G Pizotyline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PMID28870136-Compound-43 + Gefitinib DCHZJNP PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pomalidomide + Gefitinib DCZZ1KR Pomalidomide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Pramipexole + Gefitinib DCS0SS5 Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Probenecid + Gefitinib DCOBFD6 Probenecid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
RAF265 + Gefitinib DCBQZ66 RAF265 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Raloxifene + Gefitinib DCESDYO Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [3]
Raloxifene + Gefitinib DCP0YXL Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Raloxifene + Gefitinib DCSYOMW Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Raloxifene + Gefitinib DCMD1Z4 Raloxifene Adenocarcinoma (Cell Line: HT29) [5]
Raloxifene + Gefitinib DCXLYWH Raloxifene Adenocarcinoma (Cell Line: HCT-15) [5]
Raloxifene + Gefitinib DCNNDYI Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Raloxifene + Gefitinib DCIK8IH Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Raloxifene + Gefitinib DC36PBP Raloxifene Melanoma (Cell Line: UACC-257) [5]
Ramelteon + Gefitinib DCUGSWQ Ramelteon Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Rifampin + Gefitinib DCB2QBY Rifampin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
RTB101 + Gefitinib DCZ9GJK RTB101 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
RTB101 + Gefitinib DC6UWIV RTB101 Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Ruxolitinib + Gefitinib DCRYTUH Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Ruxolitinib + Gefitinib DCQ8WK8 Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Ruxolitinib + Gefitinib DCQKW7W Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Ruxolitinib + Gefitinib DCUX7F9 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Ruxolitinib + Gefitinib DCLBMRG Ruxolitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Ruxolitinib + Gefitinib DCB831U Ruxolitinib Glioma (Cell Line: SF-268) [3]
Ruxolitinib + Gefitinib DCV0SIQ Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Ruxolitinib + Gefitinib DCX83JW Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Ruxolitinib + Gefitinib DCY3734 Ruxolitinib Adenocarcinoma (Cell Line: NCIH23) [5]
Ruxolitinib + Gefitinib DCUUSWP Ruxolitinib Adenocarcinoma (Cell Line: A549) [5]
Ruxolitinib + Gefitinib DCM0Y09 Ruxolitinib Amelanotic melanoma (Cell Line: M14) [5]
Ruxolitinib + Gefitinib DCXD1ET Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Ruxolitinib + Gefitinib DCJ1C7F Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Ruxolitinib + Gefitinib DCDAV6W Ruxolitinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Ruxolitinib + Gefitinib DCXM1VV Ruxolitinib Melanoma (Cell Line: UACC-257) [5]
Ruxolitinib + Gefitinib DCOVCH8 Ruxolitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Ruxolitinib + Gefitinib DC0HVPD Ruxolitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
SCH 727965 + Gefitinib DCOO1RZ SCH 727965 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
SCH 727965 + Gefitinib DCA6DQ1 SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Sivelestat + Gefitinib DC29OBK Sivelestat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
SNDX-275 + Gefitinib DCO838A SNDX-275 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Sorafenib + Gefitinib DCASRLQ Sorafenib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sumatriptan + Gefitinib DC0ZRF8 Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tacrine + Gefitinib DCZWSB9 Tacrine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tamoxifen + Gefitinib DCUA0AX Tamoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Terameprocol + Gefitinib DC1H55W Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Testosterone + Gefitinib DCWP8OE Testosterone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Testosterone cypionate + Gefitinib DCXWCTK Testosterone cypionate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
THAPSIGARGIN + Gefitinib DCGSUIN THAPSIGARGIN Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
THAPSIGARGIN + Gefitinib DCGMGCM THAPSIGARGIN Primitive neuroectodermal tumor (Cell Line: TC-32) [3]
Theophylline + Gefitinib DCT43CP Theophylline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tiagabine + Gefitinib DC7X6TL Tiagabine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tolazoline + Gefitinib DC401G5 Tolazoline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Tolvaptan + Gefitinib DCZ5CPL Tolvaptan Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Topotecan + Gefitinib DCMSXHM Topotecan Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Tranexamic acid + Gefitinib DCFUUFG Tranexamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Trazodone + Gefitinib DC8V1M5 Trazodone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Triapine + Gefitinib DCCIQ12 Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Triflupromazine + Gefitinib DCUQL8A Triflupromazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Triiodothyronine + Gefitinib DC4KXOZ Triiodothyronine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Trimethobenzamide + Gefitinib DCHQWR6 Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Trioxsalen + Gefitinib DCQK3SO Trioxsalen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Ursodeoxycholic acid + Gefitinib DCBPKHZ Ursodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Valproic Acid + Gefitinib DCR6LZD Valproic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Vandetanib + Gefitinib DC3W8NO Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vandetanib + Gefitinib DCRSHFK Vandetanib Carcinoma (Cell Line: MCF7) [4]
Vandetanib + Gefitinib DCCIPNM Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vandetanib + Gefitinib DCOQSAO Vandetanib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vandetanib + Gefitinib DC45NA3 Vandetanib Adenocarcinoma (Cell Line: A549) [5]
Vandetanib + Gefitinib DCE8Y87 Vandetanib Adenocarcinoma (Cell Line: NCIH23) [5]
Vandetanib + Gefitinib DC1DLR7 Vandetanib Adenocarcinoma (Cell Line: HCT-15) [5]
Vandetanib + Gefitinib DCR65IJ Vandetanib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vandetanib + Gefitinib DCJ3ZN3 Vandetanib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vandetanib + Gefitinib DC5VZ1U Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vandetanib + Gefitinib DCO6H5B Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vandetanib + Gefitinib DCWE7RY Vandetanib Amelanotic melanoma (Cell Line: M14) [5]
Vandetanib + Gefitinib DCUIGWN Vandetanib Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vandetanib + Gefitinib DCZPNOM Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vandetanib + Gefitinib DC2KYK8 Vandetanib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vandetanib + Gefitinib DCQOGJZ Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vandetanib + Gefitinib DC7CYH5 Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vandetanib + Gefitinib DC70PY9 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vandetanib + Gefitinib DC4YN9X Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vandetanib + Gefitinib DC0HGN8 Vandetanib Glioma (Cell Line: SF-539) [5]
Vandetanib + Gefitinib DCO2FND Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vandetanib + Gefitinib DC4HZS9 Vandetanib Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vandetanib + Gefitinib DCRO3MC Vandetanib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vandetanib + Gefitinib DC7GFTN Vandetanib Malignant melanoma (Cell Line: UACC62) [5]
Vandetanib + Gefitinib DCK9P0P Vandetanib Melanoma (Cell Line: UACC-257) [5]
Vandetanib + Gefitinib DC0II00 Vandetanib Melanoma (Cell Line: SK-MEL-2) [5]
Vandetanib + Gefitinib DC8SMH3 Vandetanib Melanoma (Cell Line: MALME-3M) [5]
Vandetanib + Gefitinib DC1646M Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vandetanib + Gefitinib DCE8WZG Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vandetanib + Gefitinib DCID8TQ Vandetanib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vandetanib + Gefitinib DCD76IS Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vemurafenib + Gefitinib DC2AACB Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vemurafenib + Gefitinib DCJ67C0 Vemurafenib Carcinoma (Cell Line: MCF7) [4]
Vemurafenib + Gefitinib DCBQUSX Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vemurafenib + Gefitinib DCUB1LX Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vemurafenib + Gefitinib DCO6NLJ Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vemurafenib + Gefitinib DC6U1Y2 Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vemurafenib + Gefitinib DCIK7PU Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vemurafenib + Gefitinib DCCN7H0 Vemurafenib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vemurafenib + Gefitinib DCUJ0WT Vemurafenib Adenocarcinoma (Cell Line: HT29) [5]
Vemurafenib + Gefitinib DC8WHM2 Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vemurafenib + Gefitinib DC4GFVV Vemurafenib Astrocytoma (Cell Line: U251) [5]
Vemurafenib + Gefitinib DCXE13I Vemurafenib Astrocytoma (Cell Line: SNB-19) [5]
Vemurafenib + Gefitinib DCRNDE8 Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vemurafenib + Gefitinib DC6UQFQ Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vemurafenib + Gefitinib DCMSG5K Vemurafenib Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vemurafenib + Gefitinib DCS8TX6 Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vemurafenib + Gefitinib DCVPJH8 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vemurafenib + Gefitinib DCM9AA0 Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vemurafenib + Gefitinib DCJ2QV9 Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vemurafenib + Gefitinib DCR45OA Vemurafenib Glioblastoma (Cell Line: SNB-75) [5]
Vemurafenib + Gefitinib DCBUHGK Vemurafenib Glioma (Cell Line: SF-539) [5]
Vemurafenib + Gefitinib DCHL0S4 Vemurafenib Glioma (Cell Line: SF-295) [5]
Vemurafenib + Gefitinib DCG3YU7 Vemurafenib Glioma (Cell Line: SF-268) [5]
Vemurafenib + Gefitinib DCTCARF Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vemurafenib + Gefitinib DCC43NM Vemurafenib Malignant melanoma (Cell Line: UACC62) [5]
Vemurafenib + Gefitinib DCNJNUN Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [5]
Vemurafenib + Gefitinib DCEFFFB Vemurafenib Melanoma (Cell Line: UACC-257) [5]
Vemurafenib + Gefitinib DCSAG88 Vemurafenib Melanoma (Cell Line: MALME-3M) [5]
Vemurafenib + Gefitinib DCDJ46P Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vemurafenib + Gefitinib DC8BXUS Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vemurafenib + Gefitinib DCQZ48G Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vemurafenib + Gefitinib DCT6D29 Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vemurafenib + Gefitinib DCBK2SN Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vemurafenib + Gefitinib DCCE4JW Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Gefitinib DC84T73 Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Gefitinib DCYQXWM Vismodegib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Gefitinib DCVRA6F Vismodegib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Gefitinib DCU7JSJ Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Gefitinib DCPIEYX Vismodegib Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Gefitinib DCB0AQM Vismodegib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Gefitinib DCW3DJ0 Vismodegib Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Gefitinib DC6XU1B Vismodegib Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Gefitinib DC7XSIJ Vismodegib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Gefitinib DCQ8RF0 Vismodegib Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Gefitinib DCJYDOC Vismodegib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Gefitinib DCYFAUE Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Gefitinib DCEH7Q1 Vismodegib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Gefitinib DCJT5KW Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Gefitinib DC0Z2CM Vismodegib Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Gefitinib DCEVQWN Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Gefitinib DC4VOZ3 Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Gefitinib DCBERGZ Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Gefitinib DCX2QCI Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Gefitinib DCW8YO7 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Gefitinib DC0PRD4 Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Gefitinib DC4SDC0 Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Gefitinib DCT9TTF Vismodegib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Gefitinib DCSU6T8 Vismodegib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Gefitinib DCR6WWE Vismodegib Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Gefitinib DCLCAQD Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Gefitinib DCYN4NG Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Gefitinib DC6COBR Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Gefitinib DCUFHDL Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Ym155 + Gefitinib DC0UTUD Ym155 Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII) [3]
Zaleplon + Gefitinib DCSLRDK Zaleplon Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Zileuton + Gefitinib DCU2GK3 Zileuton Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1263 DrugCom(s)
33 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fulvestrant + Gefitinib DCFS5CS Fulvestrant Stage IV Lung Cancer [6]
Fulvestrant + Gefitinib DCQXZ21 Fulvestrant Estrogen Receptor-positive Breast Cancer [7]
Gefitinib + Erlotinib DCBK20C Erlotinib Non-squamous, Non-Small Cell Lung Cancer [8]
Gefitinib + Al3818 DCEQAP5 Al3818 Non-Small-Cell Lung [9]
Gefitinib + Dexamethasone DCEWV4X Dexamethasone Bladder Cancer [10]
Gefitinib + Everolimus DC0QVJU Everolimus Lung Cancer [11]
Gefitinib + Pemetrexed DC32TE0 Pemetrexed Carcinoma, Non Small Cell Lung [12]
Gefitinib + Capmatinib DC4BJ6N Capmatinib Non-small Cell Lung Cancer [13]
Gefitinib + Celecoxib DC7BRR3 Celecoxib Lung Cancer [14]
Gefitinib + Topotecan DC7V5UU Topotecan Ovarian Cancer [15]
Gefitinib + Capecitabine DC9RNOF Capecitabine Unspecified Adult Solid Tumor, Protocol Specific [16]
Gefitinib + Docetaxel DCDSSKB Docetaxel Breast Cancer [17]
Gefitinib + Everolimus DCJCM9J Everolimus Brain and Central Nervous System Tumors [18]
Gefitinib + Tamoxifen DCL2W27 Tamoxifen Breast Neoplasms [19]
Gefitinib + Docetaxel DCMPLO1 Docetaxel Non-small Cell Lung Cancer [20]
Gefitinib + Simvastatin DCNVKWM Simvastatin Lung Cancer [21]
Gefitinib + Al3818 DCORLUW Al3818 Non-squamous Non-small Cell Lung Cancer [22]
Gefitinib + Anastrozole DCQPDOM Anastrozole Estrogen Receptor-positive Breast Cancer [7]
Gefitinib + EGF816 DCFP9A7 EGF816 EGFR-mutant Non-small Cell Lung Cancer [23]
Gefitinib + Savolitinib DCFXTAY Savolitinib Non-Small Cell Lung Cancer [24]
Gefitinib + Tepotinib DCPELRY Tepotinib Non-small Cell Lung Cancer [25]
Gefitinib + Osimertinib DCXPKLY Osimertinib Non-Small Cell Lung Cancer [26]
Gefitinib + Carboplatin DCGU6CO Carboplatin Adenocarcinoma of the Lung [27]
Gefitinib + Vinorelbine DC19DHY Vinorelbine Non Small Cell Lung Cancer [28]
Gefitinib + Fruquintinib DC552OD Fruquintinib NSCLC [29]
Gefitinib + EGF816 DC5PKWD EGF816 Lung Cancer [30]
Gefitinib + Erlotinib DC7ZR22 Erlotinib Non-small Cell Lung Cancer [31]
Gefitinib + Osimertinib DCVVUG8 Osimertinib Non-Small Cell Lung Cancer [32]
Gefitinib + Pemetrexed DC2J8AA Pemetrexed Lung Neoplasms [33]
Gefitinib + Erlotinib DC8A9UP Erlotinib Non-small Cell Lung Cancer (NSCLC) [34]
Gefitinib + Al3818 DCBHRAJ Al3818 Lung Cancer, Nonsmall Cell [35]
Rivoceranib + Gefitinib DCVAMTB Rivoceranib EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors [36]
Gefitinib + Icotinib hydrochloride DC6LBVW Icotinib hydrochloride Non-Small-Cell Lung Cancer [37]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DrugCom(s)

References

1 Gefitinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT01556191) Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
7 ClinicalTrials.gov (NCT00057941) Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
8 ClinicalTrials.gov (NCT04179890) The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
9 ClinicalTrials.gov (NCT03766490) Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
10 ClinicalTrials.gov (NCT00479089) Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
11 ClinicalTrials.gov (NCT00096486) Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
12 ClinicalTrials.gov (NCT01469000) A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
13 ClinicalTrials.gov (NCT01610336) A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
14 ClinicalTrials.gov (NCT00068653) Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
15 ClinicalTrials.gov (NCT00317772) Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
16 ClinicalTrials.gov (NCT00039390) Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
17 ClinicalTrials.gov (NCT00086957) Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
18 ClinicalTrials.gov (NCT00085566) Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
19 ClinicalTrials.gov (NCT00229697) Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
20 ClinicalTrials.gov (NCT00048087) Iressa/Docetaxel in Non-Small-Cell Lung Cancer
21 ClinicalTrials.gov (NCT00452244) Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
22 ClinicalTrials.gov (NCT03602027) Phase I Study of the Combination of Anlotinib With Gefitinib
23 ClinicalTrials.gov (NCT03333343) Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
24 ClinicalTrials.gov (NCT02374645) A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
25 ClinicalTrials.gov (NCT01982955) MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT03122717) Osimertinib and Gefitinib in EGFR Inhibitor nave Advanced EGFR Mutant Lung Cancer
27 ClinicalTrials.gov (NCT00040794) Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
28 ClinicalTrials.gov (NCT02319577) GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
29 ClinicalTrials.gov (NCT02976116) A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
30 ClinicalTrials.gov (NCT03292133) A Study of EGF816 and Gefitinib in TKI-nave EGFR-mutant Non-Small Cell Lung Cancer
31 ClinicalTrials.gov (NCT03653546) First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
32 ClinicalTrials.gov (NCT03944772) Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
33 ClinicalTrials.gov (NCT02518802) Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
34 ClinicalTrials.gov (NCT02588261) A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
35 ClinicalTrials.gov (NCT04028778) Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
36 ClinicalTrials.gov (NCT02824458) A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
37 ClinicalTrials.gov (NCT02031601) Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer